Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Dharmalingam, Mala; Yamasandhi, P Ganavi

doi:10.4103/ijem.ijem_585_17

Cited by 162 publications

(128 citation statements)

References 57 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Particularly, ZAG exhibits the attenuation of diseases associated with obesity, e.g., NAFLD [ 125 , 126 ]. NAFLD is a prevalent complication of T2DM [ 127 ]. ZAG can play a certain role in T2DM.…”

Section: Promising Agents Involved In Regulating Semicarbazide-senmentioning

confidence: 99%

Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus

2020

View full text Add to dashboard Cite

Creatine supplementation of the population with type 2 diabetes mellitus (T2DM) combined with an exercise program is known to be a possible therapy adjuvant with hypoglycemic effects. However, excessive administration of creatine leads to the production of methylamine which is deaminated by the enzyme semicarbazide-sensitive amine oxidase (SSAO) and as a result, cytotoxic compounds are produced. SSAO activity and reaction products are increased in the serum of T2DM patients. Creatine supplementation by diabetics will further augment the activity of SSAO. The current review aims to find a feasible way to ameliorate T2DM for patients who exercise and desire to consume creatine. Several natural agents present in food which are involved in the regulation of SSAO activity directly or indirectly are reviewed. Particularly, zinc-α2-glycoprotein (ZAG), zinc (Zn), copper (Cu), histamine/histidine, caffeine, iron (Fe), and vitamin D are discussed. Inhibiting SSAO activity by natural agents might reduce the potential adverse effects of creatine metabolism in population of T2DM.

show abstract

Section: Promising Agents Involved In Regulating Semicarbazide-senmentioning

confidence: 99%

Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus

2020

View full text Add to dashboard Cite

show abstract

“…Hypercholesterolemia is main cause of the NAFLD and ultrasound-based imaging techniques are cheaper and more widely available to diagnose NAFLD in the field of gastroenterology. [1] Parkinson disease (PD) is the second most common non-demyelinizan neurologic disase and its incidence is steadily increasing in the world. Although the etiology of PD remains unclear, detoriated cholesterol mechanism have been implicated in pathogenesis of PD.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Non Alcoholic Fatty Liver Disease in patients with Parkinson Disease

Vural¹

2019

Anatol JFM

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has presented as the most common cause of chronic liver disease in the Western world. Parkinson disease (PD) is these most common non-demyelinizan neurologic disase and its incidence is steadily increasing in the world. Our study aims to analyze the prevalence of ultrasonography-proven NAFLD among the PD patients. Methods: A retrospective chart review was performed to identify PD patients who had at least two visits in the Liver Clinic from January 2017 to May 2018. Thus, 124 consecutive patients with PD was longitudinally screened for NAFLD which were diagnosed according to ultrasonographic criteria. Control subjects were selected from age-matched eldely subjects. Demographic and laboratory data, concurrent statin use and results of hepatobiliary ultrasonography were collected. Results: Non-alcoholic fatty liver disease prevalence was significantly lower in the PD group than in the agematched control group (21.0% vs. 36.9%, p=0.014). In multiple logistic regression analyses using baseline factors, statin use, elevated HbA1c, baseline fasting glucose below than 100 mg/dL, and elevated ALT levels were independently associated with NAFLD (p=0.040, p<0.001, p=0.030, and p<0.001, respectively). Conclusion: While additional studies in large populations are needed to investigate the correlation between PD and NAFLD, further exploration of PD-related metabolic liver disease clinically appears warranted.

show abstract

“…Non-alcoholic steato-hepatitis is a common complication among the patients with type 2 diabetes mellitus with a prevalence of 70% and they usually co-exist as manifestation of the metabolic syndrome, which is marked with high level of insulin resistance among these patients [7,8]. To add to this complication of diabetes mellitus, a meta-analysis report concluded that the patients with diabetes mellitus may be associated with elevated risk of hepatocellular carcinoma incidence and mortality, furthermore, patients with diabetes have poor prognosis compared to their counterparts [9,10].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review

Mirghani¹,

Thaniyath²,

Elfakki³

2019

Biol Med

View full text Add to dashboard Cite

The drug category of Sodium-Glucose co-transporters 2 inhibitors (SGLT 2 inhibitors) is a newer class of pharmaceutical agents for the management of type-2 diabetes mellitus, with a proved promising cardio-protective effects. In addition to above beneficial effects, Sodium-Glucose co-transporters 2 inhibitors showed their effectiveness to reduce abdominal fat content, amount of fat in liver tissues and progression of inflammation and fibrosis in experimental as well as clinical studies. Non-Alcoholic Fatty Liver Diseases (NAFLD) are common among patients with type 2 diabetes patients and includes fatty liver, Non-Alcoholic Steato-Hepatitis (NASH) and cirrhosis and when present together these disorders exacerbates each other deleterious consequences. This review article is carried out with an objective to find out the effects of Sodium-Glucose co-transporters 2 inhibitors on non-alcoholic fatty liver diseases, steato-hepatitis, fibrosis liver and hepatocellular carcinoma. The authors identified 21 relevant articles including twelve experimental and nine clinical studies with inclusion of 15152 patients, in study period ranges from 20-104 weeks. The analysis of these studies showed beneficial effects SGLT 2 inhibitors on fatty liver, liver function and NASH development, hepatic fibrosis and prevention and regression of hepatocellular carcinoma and concluded that SGLT-2 inhibitors may protect or reduce the incidence of non-alcoholic fatty liver diseases, steato-hepatitis and hepatic fibrosis in type 2 diabetes patients.

show abstract

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Cited by 162 publications

References 57 publications

Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus

Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus

Prevalence of Non Alcoholic Fatty Liver Disease in patients with Parkinson Disease

The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review

Contact Info

Product

Resources

About